News
PASG
4.440
-0.89%
-0.040
Weekly Report: what happened at PASG last week (0810-0814)?
Weekly Report · 4d ago
TD Cowen Sticks to Their Hold Rating for Passage Bio (PASG)
TipRanks · 08/11 06:45
Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate
Benzinga · 08/10 11:45
Weekly Report: what happened at PASG last week (0803-0807)?
Weekly Report · 08/10 09:43
Weekly Report: what happened at PASG last week (0727-0731)?
Weekly Report · 08/03 09:43
Weekly Report: what happened at PASG last week (0720-0724)?
Weekly Report · 07/27 09:46
Weekly Report: what happened at PASG last week (0713-0717)?
Weekly Report · 07/20 09:44
Weekly Report: what happened at PASG last week (0706-0710)?
Weekly Report · 07/13 09:45
Weekly Report: what happened at PASG last week (0629-0703)?
Weekly Report · 07/06 09:47
Major Investor Quietly Boosts Stake in Biotech Player
TipRanks · 06/30 02:03
Weekly Report: what happened at PASG last week (0622-0626)?
Weekly Report · 06/29 09:44
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired
NASDAQ · 06/26 14:33
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 06/25 17:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 06/25 12:05
Passage Bio And Remix Therapeutics Enter All-Stock Merger Agreement; Stock Down
NASDAQ · 06/25 08:15
Passage Bio Shares Slide on Merger with Remix Therapeutics
Dow Jones · 06/24 22:43
9 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 06/24 21:05
Passage Bio Merges with Remix Therapeutics in All-Stock Deal
TipRanks · 06/24 20:52
Passage Bio trading resumes
TipRanks · 06/24 20:40
Passage Bio to Be Absorbed by Remix Therapeutics
Dow Jones · 06/24 20:23
More
Webull provides a variety of real-time PASG stock news. You can receive the latest news about Passage Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.